Institution
Rush University Medical Center
Healthcare•Chicago, Illinois, United States•
About: Rush University Medical Center is a healthcare organization based out in Chicago, Illinois, United States. It is known for research contribution in the topics: Population & Dementia. The organization has 13915 authors who have published 29027 publications receiving 1379216 citations. The organization is also known as: Rush Presbyterian St. Luke's Medical Center.
Topics: Population, Dementia, Transplantation, Cognitive decline, Health care
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Current group-wide ECOG trials in stage IV NSCLC consist of randomized phase II trials evaluating single agents, and life-threatening and lethal toxicities were greater on the combination regimens than on the single agents.
Abstract: During the last decade, the Eastern Cooperative Oncology Group (ECOG) has studied a series of combination chemotherapy regimens in metastatic (stage IV) non-small-cell lung cancer (NSCLC). In January 1984, the ECOG activated a randomized study, EST 1583, which concluded the evaluation of combination regimens in phase III trials and initiated the evaluation of single agents exclusively in previously untreated patients. The treatment regimens in EST 1583 consisted of: (1) mitomycin, vinblastine, and cisplatin (MVP); (2) vinblastine and cisplatin (VP); (3) MVP alternating with the regimen cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP); (4) carboplatin followed by the MVP regimen at the time of progression; and (5) iproplatin followed by MVP at the time of progression. From January 1984 to July 1985, 743 patients were entered on this trial and 699 fulfilled the eligibility requirements. The following objective response rates (complete plus partial remissions) were observed: first-line MV...
332 citations
••
TL;DR: Vitamin E intake, from foods or supplements, is associated with less cognitive decline with age, and there was little evidence of association with vitamin C or carotene intake.
Abstract: Background Previous studies raise the possibility that antioxidants protect against neurodegenerative diseases. Objective To examine whether intake of antioxidant nutrients, including vitamin E, vitamin C, and carotene, is associated with reduced cognitive decline with age. Design Longitudinal population-based study conducted from September 17, 1993, to November 20, 2000, with an average follow-up of 3.2 years. Patients The patients were 2889 community residents, aged 65 to 102 years, who completed a food frequency questionnaire, on average 18 months after baseline. Main Outcome Measure Cognitive change as measured by 4 tests (the East Boston Memory Test, which tests immediate and delayed recall; the Mini-Mental State Examination; and the Symbol Digit Modalities Test) at baseline and 3 years for all participants, and at 6 months for 288 randomly selected participants. Results We used random-effects models to estimate nutrient effects on individual change in the average score of the 4 cognitive tests. The cognitive score declined on average by 5.0 × 10 −2 standardized units per year. There was a 36% reduction in the rate of decline among persons in the highest quintile of total vitamin E intake (−4.3 × 10 −2 standardized units per year) compared with those in the lowest quintile (−6.7 × 10 −2 standardized units per year) ( P = .05), in a model adjusted for age, race, sex, educational level, current smoking, alcohol consumption, total calorie (energy) intake, and total intakes of vitamin C, carotene, and vitamin A. We also observed a reduced decline with higher vitamin E intake from foods ( P = .03 for trend). There was little evidence of association with vitamin C or carotene intake. Conclusion Vitamin E intake, from foods or supplements, is associated with less cognitive decline with age.
331 citations
••
TL;DR: Test the hypothesis that preterm infants, siblings of infants who died of SIDS, and infants who have experienced an idiopathic, apparent life-threatening event have a greater risk of cardiorespiratory events than healthy term infants.
Abstract: ContextHome monitors designed to identify cardiorespiratory events are frequently
used in infants at increased risk for sudden infant death syndrome (SIDS),
but the efficacy of such devices for this use is unproven.ObjectiveTo test the hypothesis that preterm infants, siblings of infants who
died of SIDS, and infants who have experienced an idiopathic, apparent life-threatening
event have a greater risk of cardiorespiratory events than healthy term infants.DesignLongitudinal cohort study conducted from May 1994 through February 1998.SettingFive metropolitan medical centers in the United States.ParticipantsA total of 1079 infants (classified as healthy term infants and 6 groups
of those at risk for SIDS) who, during the first 6 months after birth, were
observed with home cardiorespiratory monitors using respiratory inductance
plethysmography to detect apnea and obstructed breathing.Main Outcome MeasuresOccurrence of cardiorespiratory events that exceeded predefined conventional
and extreme thresholds as recorded by the monitors.ResultsDuring 718 358 hours of home monitoring, 6993 events exceeding
conventional alarm thresholds occurred in 445 infants (41%). Of these, 653
were extreme events in 116 infants (10%), and of those events with apnea,
70% included at least 3 obstructed breaths. The frequency of at least 1 extreme
event was similar in term infants in all groups, but preterm infants were
at increased risk of extreme events until 43 weeks' postconceptional age.ConclusionsIn this study, conventional events are quite common, even in healthy
term infants. Extreme events were common only in preterm infants, and their
timing suggests that they are not likely to be immediate precursors to SIDS.
The high frequency of obstructed breathing in study participants would likely
preclude detection of many events by conventional techniques. These data should
be important for designing future monitors and determining if an infant is
likely to be at risk for a cardiorespiratory event.
330 citations
••
TL;DR: PICALM regulated PICALM/clathrin-dependent internalization of Aβ bound to the low density lipoprotein receptor related protein-1, a key Aβ clearance receptor, and guided Aβ trafficking to Rab5 and Rab11, leading to Aβ endothelial transcytosis and clearance.
Abstract: PICALM is a highly validated genetic risk factor for Alzheimer's disease (AD). We found that reduced expression of PICALM in AD and murine brain endothelium correlated with amyloid-β (Aβ) pathology and cognitive impairment. Moreover, Picalm deficiency diminished Aβ clearance across the murine blood-brain barrier (BBB) and accelerated Aβ pathology in a manner that was reversible by endothelial PICALM re-expression. Using human brain endothelial monolayers, we found that PICALM regulated PICALM/clathrin-dependent internalization of Aβ bound to the low density lipoprotein receptor related protein-1, a key Aβ clearance receptor, and guided Aβ trafficking to Rab5 and Rab11, leading to Aβ endothelial transcytosis and clearance. PICALM levels and Aβ clearance were reduced in AD-derived endothelial monolayers, which was reversible by adenoviral-mediated PICALM transfer. Inducible pluripotent stem cell-derived human endothelial cells carrying the rs3851179 protective allele exhibited higher PICALM levels and enhanced Aβ clearance. Thus, PICALM regulates Aβ BBB transcytosis and clearance, which has implications for Aβ brain homeostasis and clearance therapy.
330 citations
••
University of California, Davis1, University of Western Ontario2, Nemours Foundation3, Children's Hospital of Philadelphia4, Nationwide Children's Hospital5, Katholieke Universiteit Leuven6, Rush University Medical Center7, Medical University of Warsaw8, University of Freiburg9, University College London10, University of Barcelona11, University of Duisburg-Essen12, Karolinska University Hospital13, University of California, Los Angeles14, University of Florida15, Boston Children's Hospital16, Instituto Politécnico Nacional17, National Institute for Health Research18, Cincinnati Children's Hospital Medical Center19, The Catholic University of America20, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico21, Vita-Salute San Raffaele University22
TL;DR: Ataluren was generally well tolerated and most treatment-emergent adverse events were mild to moderate in severity, and there was a significant effect of ataluren in the prespecified subgroup of patients in the intention-to-treat population.
330 citations
Authors
Showing all 14032 results
Name | H-index | Papers | Citations |
---|---|---|---|
John Q. Trojanowski | 226 | 1467 | 213948 |
Virginia M.-Y. Lee | 194 | 993 | 148820 |
Luigi Ferrucci | 193 | 1601 | 181199 |
David A. Bennett | 167 | 1142 | 109844 |
Todd R. Golub | 164 | 422 | 201457 |
David Cella | 156 | 1258 | 106402 |
M.-Marsel Mesulam | 150 | 558 | 90772 |
John D. E. Gabrieli | 142 | 480 | 68254 |
David J. Kupfer | 141 | 862 | 102498 |
Clifford B. Saper | 136 | 406 | 72203 |
Pasi A. Jänne | 136 | 685 | 89488 |
Nikhil C. Munshi | 134 | 906 | 67349 |
Martin B. Keller | 131 | 541 | 65069 |
Michael E. Thase | 131 | 923 | 75995 |
Steven R. Simon | 129 | 1090 | 80331 |